Business Context and Reporting Period
Instil Bio, Inc. filed this Form 8-K on September 6, 2022, reporting events occurring on September 2 and September 6, 2022. The filing concerns executive leadership changes and related compensation arrangements; it does not provide quarterly financial results.
Key Financial and Operating Information
- No revenue, profit, cash flow, margin, debt, liquidity, or other financial metrics are reported.
- Timothy L. Moore was appointed Chief Operating Officer effective September 6, 2022.
- Mr. Moore’s annual base salary is $565,000, with a $100,000 signing and retention bonus.
- His initial target annual cash bonus is 50% of base salary, prorated for 2022 based on his period of service.
- The company granted Mr. Moore an option to purchase 750,000 common shares at an exercise price equal to the Nasdaq closing price on the effective date.
- The option vests 25% after one year, with the balance vesting in substantially equal monthly installments over the following 36 months, subject to continued service.
Material Changes Versus the Prior Comparable Period
- Mr. Moore joined as Chief Operating Officer after serving as President and Chief Operating Officer of PACT Pharma and previously holding senior technical operations roles at Kite Pharma and Genentech.
- Chief Technical Officer Vijay Chiruvolu, Ph.D., resigned, and his employment terminated on September 2, 2022.
- The filing does not present comparable-period financial information or quantify the effect of these changes on operating results.
Guidance, Outlook, Risks, Contingencies, and Unusual Items
- No financial guidance or formal business outlook is provided.
- Mr. Moore’s employment agreement provides for severance of 12 months of base salary, earned bonuses, and 12 months of benefits upon qualifying termination outside a change-in-control period, subject to a release of claims.
- For qualifying termination during the change-in-control period, he may receive 12 months of base salary, a target bonus equal to 50% of then-current base salary, earned bonuses, 12 months of benefits, and full acceleration of equity awards.
- Outside the change-in-control period, time-based equity awards may receive six months of additional vesting acceleration upon qualifying termination.
- The company also entered into confidentiality, invention-assignment, non-solicitation, non-competition, and indemnification agreements with Mr. Moore.
- The employment agreement is summarized in the 8-K and was expected to be filed as an exhibit to the company’s Form 10-Q for the quarter ending September 30, 2022.
Investor Verification Priorities
- Verify the final employment agreement and option award agreement when filed, including termination, change-in-control, and vesting provisions.
- Confirm the exercise price and accounting treatment of the 750,000-share option grant.
- Assess the operational impact of the Chief Technical Officer’s departure and the new Chief Operating Officer appointment.
- Review subsequent filings for changes in executive compensation, equity dilution, liquidity, and clinical or operating outlook.